VEGF and angiopoietin signaling in tumor angiogenesis and metastasis

Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as additional conduits for metastatic spread. The identification of growth factor receptor pathways regulating angiogenesis has led to the clinical approval of the first antiangiogenic molecules targeted against t...

Full description

Saved in:
Bibliographic Details
Published in:Trends in molecular medicine 2011-07, Vol.17 (7), p.347-362
Main Authors: Saharinen, Pipsa, Eklund, Lauri, Pulkki, Kristina, Bono, Petri, Alitalo, Kari
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - metabolism
Angiopoietins - antagonists & inhibitors
Angiopoietins - genetics
Animals
Gene Expression Regulation, Neoplastic
Humans
Lymphatic Vessels - metabolism
Models, Animal
Neoplasm Metastasis - genetics
Neoplasm Metastasis - pathology
Pathology
Receptors, TIE - metabolism
Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
Signal Transduction
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Vascular Endothelial Growth Factor A - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as additional conduits for metastatic spread. The identification of growth factor receptor pathways regulating angiogenesis has led to the clinical approval of the first antiangiogenic molecules targeted against the vascular endothelial growth factor (VEGF)–VEGF receptor (VEGFR)-2 pathway. However, in many cases resistance to anti-VEGF–VEGFR therapy occurs, and thus far the clinical benefit has been limited to only modest improvements in overall survival. Therefore, novel treatment modalities are required. Here, we discuss the members of the VEGF–VEGFR family as well as the angiopoietin growth factors and their Tie receptors as potential novel targets for antiangiogenic and antilymphangiogenic therapies.
ISSN:1471-4914
1471-499X
DOI:10.1016/j.molmed.2011.01.015